The draft resolution:

**Strengthening Local Production of Medicines and Other Health Technologies to Improve Access**

**PP 1.** Recalling resolutions WHA60.20 (2007), WHA61.21 (2008), WHA62.16 (2009); WHA63.12 (2010), WHA65.17 (2012), WHA65.19 (2012), WHA66.22 (2013), WHA67.20 (2014), WHA67.21 (2014), WHA67.22 (2014), WHA68.7 (2015), WHA71.8 (2018), WHA72.8 (2019), all of which encompass aspects of the need to promote access to the quality, safe, effective and affordable medicines and other health technologies[[1]](#footnote-1);

**PP 2.** Recalling resolution WHA61.21 (2008), decision WHA 71(9) (2018), and document A71/12 (2018), insofar as they address the role of technology transfer and local production of medicines and other health technologies in improving access;

**PP 3.** Recalling also UNGA resolution A/RES/74/306 (2020) and WHA A73/CONF./1Rev.1 (2020) on Comprehensive and coordinated response to the coronavirus disease (COVID-19) pandemic which call for intensified international cooperation and solidarity to contain, mitigate and overcome the pandemic and its consequences through responses that are people-centred and gender-sensitive, with full respect for human rights;

**PP 4.** Recalling also the Human Rights Council resolution RES/12/24 (2009) on access to medicine in the context of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health;

**PP 5.** Recalling further the 2030 Agenda for Sustainable Development and its aim of ensuring that no one is left behind;

 [PP5bis alt alt.

[Reaffirming the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) as amended, and also reaffirming the 2001 WTO Doha Declaration on the TRIPS Agreement and Public Health, which recognizes that the TRIPS Agreement should be interpreted and implemented in a manner supportive of the right of Member States to protect public health and, in particular, to promote access to medicines for all, [including considering as appropriate, time limited waivers of some specified provisions related to COVID-19 products and technologies; Japan, USA, UK, Australia, Switzerland reserve; South Africa, Eswatini, Kenya, Zimbabwe retain] [and notes the need for appropriate incentives in the development of new health products.; USA add; Japan, Switzerland, Australia, Canada, Egypt support; Argentina delete] and also recognising that intellectual property rights are an important incentive for the development of new health care products; Chair proposed, South Africa, Eswatini support] [Argentina alternate to last part: and recognizing that intellectual property protection is important for the development of new medicines, as well as the concerns about its effects on prices; Egypt support]

**PP 6.** Acknowledging Member States’ commitment to achieve the Sustainable Development Goals [including those which relate to local production of medicines and other health technologies in various ways (e.g. SDG3, SDG8, SDG9);

PP.6 bis. Recognizing that some countries face problems in accessing medicines, vaccines and other essential health technologies due to factors such as low manufacturing capacity and high prices, among others, and that such problems can be exacerbated in times of public health emergencies and/or overwhelming demand, such as during the COVID-19 pandemic;

**PP7** Recalling WHO’s roadmap for access to medicines, vaccines and other health products 2019-2023[[2]](#footnote-2) as part of comprehensive support for access and strategic local production while considering regional plans and initiatives;

**PP 8.** Emphasizing the need to improve access to quality, safe, effective and affordable medicines and other health technologies, inter alia, through building capacity for local production, especially in LMICs, technology transfer on voluntary and mutually agreed terms, cooperation [with, support to and] development of voluntary patent pools and other voluntary initiatives, [such as WHO Covid-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool,; Switzerland reserve; Costa Rica, Brazil, South Africa, Norway, Argentina, Indonesia, Kenya retain] and promoting generic competition in line WHO’s road map for access to medicines, vaccines and other health products 2019–2023;

**PP 10.** Recognizing that integration of local production into the overall health systems strengthening can contribute to sustainable access to quality-assured safe, effective and affordable medicines and other health technologies, help prevent or address medical product shortages, achieving universal health coverage and strengthening of national health emergency preparedness and response and minimizing public health hazards;

**PP 11.** Recognizing also that local production can contribute to other national development goals, such as catalysing local capacity in innovation, strengthening human capital and expertise and building a knowledge-based economy;

**PP11bis.** Recognizing further that the COVID-19 pandemic has highlighted the critical need to prepare for potential disruptions of the supply chain for essential medicines and other health technologies[, including through the strengthening of local production;

**PP11 bis bis.** Recognizing the importance of promoting competition to improve availability and affordability of health technologies consistent with public health policies and needs, inter alia through the production and introduction of generic versions, in particular of essential medicines, in developing countries;

**PP11ter.** Noting that the local production of medicines and other health technologies can provide for greater sustainability of supply chains, especially in public health emergencies;

**PP 12.** Noting that the interagency statement on promoting local production[[3]](#footnote-4) signed by the six organizations (The Global Fund, UNAIDS, UNCTAD, UNICEF, UNIDO and WHO) calls for a holistic approach, close partnership, inter-ministerial and relevant stakeholder cooperation, and global synergy in promoting quality and sustainable local production of safe, effective, quality and affordable medicines and other health technologies;

PP12bis. Recognizing the work of the inter-agency pharmaceutical cooperation group hosted by the WHO and the role of Unitaid and the Medicines Patent Pool to help countries enhance the access to medicines particularly for HIV/AIDS, tuberculosis and malaria, etc.;

**PP 13.** Recalling also the launch of the Access to COVID-19 Tools (ACT) Accelerator, which is a global collaboration that seeks to accelerate development, production, and equitable access to COVID-19 diagnostics, therapeutics, and vaccines and strengthen health systems;

**PP 14.** Noting that, with globalization and the variety of country contexts, there is no “one size fits all” approach in promoting local production;

**PP 16.** Recognizing the small size of some Member States economies poses a challenge for local production, which could be addressed by regional market integration;

**PP 17**. Emphasizing the need to ensure the quality, safety, efficacy, effectiveness and affordability of locally-produced medicines and other health technologies including through effective manufacturing and regulatory systems;

**PP 19.** Noting that the benefits and sustainability of local production is dependent on, among others, a functioning pharmaceutical value chain: from research & development, manufacturing and regulation through to pricing and reimbursement, supply chains, and prescribing and dispensing by health workers as well as stewardship to ensure judicious and appropriate use;

**PP 20.** Acknowledging with appreciation the many existing national, regional and global efforts, as well as the achievements made by the Member States, to promote quality and sustainable local production of [safe, effective and affordable medicines and other health technologies to benefit public health needs;

**PP 21.** Noting that local production can contribute towards achieving the Triple Billion goals of the WHO 13th General Programme of Work;

**PP 22.** Noting with concern that Member States still face many challenges in establishing and strengthening sustainable local production of quality-assured, safe, effective and affordable medicines and other health technologies to benefit public health systems and public health needs,

1. **Urge Member States[[4]](#footnote-5):**

**OP 1.** Where appropriate, based on the national context,

**OP1.1.** to strengthen their leadership, commitment and support in promoting to establish and strengthen quality and sustainable local production of medicines and other health technologies which follows good manufacturing practices;

**OP1.2.** to align their national and regional policies and strategies related to local production and leverage regional economic integration and coordination platforms to support products with sizeable regional demand to expand access to markets and enhance sustainability of local production;

**OP1.3** to develop evidence-based holistic national and regional policies, financing mechanisms, strategies and plans of action and to explore appropriate mechanisms to support the sustainable implementation of the national/regional strategies for local production in collaboration with stakeholders for strengthening the local production of quality, safe, effective and affordable medicines and other health technologies;

**OP1.5.** to enhance inter-ministerial policy coherence and to create incentives and an enabling business environment for local production to be quality-assured and sustainable;

**OP1.6.** to apply a holistic approach in strengthening local production by considering, for example, promoting research and development, transparency of markets for medicines and other health technologies, regulatory systems strengthening, access to sustainable and affordable financing, development of skilled human resources, access to technology transfer on voluntary and mutually agreed terms for production and needs-based innovation, the aggregation of national and regional demand, appropriate incentives for private-sector investment, particularly in the context of achieving universal health coverage;

**OP1.7.** to engage in global, regional and subregional networks related to promoting sustainable local production of quality, safe, effective and affordable medicines, and to further enhance multi-stakeholder collaboration;

**OP1.8.** to further engage in North–South and South–South development cooperation, partnerships and networks to build and improve the transfer of technology related to health innovation on voluntary and mutually-agreed terms [and in line with their international obligations; Egypt retain; Argentina support; USA reserve]

OP 1.10 To [take into account the rights and obligations; Brazil suggestion] [fully use the flexibilities contained; Brazil suggest to delete] in the TRIPs Agreement, including those affirmed by the Doha declaration on the TRIPS agreement and public health, in order to promote access to medicines and other health technologies for all; Egypt propose alt; Switzerland delete

1. **Request the Director General:**

OP2bis. To continue to support Member States by strengthening actions related to WHA61.21 and WHA66.22, WHA67.20;

**OP2.1.** to strengthen the WHO’s role in providing leadership and direction in promoting the strategic use of quality, accessible and affordable and sustainable local production of medicines and other health technologies by using a holistic approach and following good manufacturing practices;

**OP2.2.** to raise awareness of the importance of sustainable local production of safe, effective, quality, and affordable medicines and other health technologies in improving access;

**OP2.3.** to continue to support Member States upon their request in promoting quality and sustainable local production of medicines and other health technologies, including, as appropriate, by:

**OP2.3.a.** providing technical support to Member States in developing and/or implementing national policies and evidence-based comprehensive strategies and plans of action for sustainable local production;

**OP2.3.b.** assisting Member States to foster strategic and collaborative partnerships, including research and manufacturing;

**OP2.3.c.** building capacity of Member States towards policy coherence and creating an enabling environment;

**OP2.3.d.** building capacity of governments and other stakeholders to strengthen local production towards quality-assurance, regulatory approval and WHO prequalification as appropriate;

**OP2.3.e.** strengthening regulatory systems and regional regulatory collaboration;

**OP2.3.f.** supporting Member States in [facilitating; Norway, Switzerland add] [research and development and; Switzerland delete; Brazil, Egypt, Argentina, Indonesia retain] technology transfer [[on voluntary and mutually agreed terms; Argentina, Egypt delete; Canada, EU, Japan retain] [and in line with their international obligations; Bangladesh add; USA, Switzerland reserve; Egypt, Argentina retain] USA, Switzerland add] for local production of [quality-assured; USA add] prioritized medicines and other health technologies to [prevent and; USA add] address shortages and/or specific public health needs;

**OP2.3.g.** exploring a mechanism for collecting and disseminating local production-related market intelligence [including by tracking the impact of local production measures on prices of local health technologies; USA add; Egypt, Ethiopia reserve] in collaboration with other relevant international organizations and agencies;

**OP2.4.** to encourage greater participation of Member States in existing regional and global initiatives for collaborations and cooperation;

**OP2.5.** to foster and coordinate with relevant international intergovernmental organizations in promoting local production in a strategic and collaborative approach;

**OP2.6.** to leverage existing and, if needed, establish new global platforms to promote transfer of technology on voluntary and mutually agreed terms [and in line with international obligations; Egypt retain; USA delete] and local production under North-South and South-South cooperation;

**OP2.7.** to continue to support local production through dedicating staff and sufficient resources to carry out activities under this resolution at all three levels of the organization;

[OP2.8. To [continue to support the application of; Canada delete] [affirm the right of WTO Members to use; Canada add] TRIPS flexibilities in order to [protect public health and, in particular; Canada add] promote [local production, [generic competition; UK, delete] and; Canada delete] access to medicines [for all; Canada add]; Argentina add; USA reserve]

(from Norway) [OP2.8 To continue to [support; Norway delete] [recognize; Norway add] the application of TRIPS flexibilities in [urgent cases to ensure; Norway add] [order to promote local production, generic competition and; Norway delete] access to medicines; Argentina add; USA reserve]

[OP2.8 alt To continue to support WTO Members to use TRIPS flexibilities in order to protect public health and ensure access to medicines for all including through promoting local production; Egypt propose; USA, Switzerland, Japan, UK reserve for 1 mention]

**OP 2.8 bis** To continue to support transparency of prices and economic data along the value chain of medicines, including locally-produced medicines, and other health technologies (including the supply chain) in order to promote access and affordability;

 **OP2.9.** To report on progress in the implementation of this resolution to the World Health Assembly biennially from 2023 to 2027.

1. medicines and other health technologies includes pharmaceuticals, vaccines, biopharmaceuticals, medicals devices etc. [↑](#footnote-ref-1)
2. <https://apps.who.int/iris/bitstream/handle/10665/330145/9789241517034-eng.pdf?ua=1> [↑](#footnote-ref-2)
3. Interagency statement on promoting local production of medicines and other health technologies. <https://www.who.int/phi/implementation/tech_transfer/Interagency-statement-on-promoting-local-production.pdf?ua=1>, accessed 7 January 2021. [↑](#footnote-ref-4)
4. And, where applicable, regional economic integration organizations. [↑](#footnote-ref-5)